A preclinical188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49

Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice

(2010) E. Dadachova et al.   CANCER BIOLOGY & THERAPY

The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size

(2009) Guozheng Liu et al.   EUROPEAN JOURNAL OF CANCER

A Semiempirical Model of Tumor Pretargeting

(2008) Guozheng Liu et al.   BIOCONJUGATE CHEMISTRY

A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours

(2008) Elisa García-Garayoa et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rhenium-188 labelled meso-tetrakis[3,4-bis(carboxymethyleneoxy)phenyl] porphyrin for targeted radiotherapy: preliminary biological evaluation in mice

(2008) Zhi-yun Jia et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector

(2008) G. Liu et al.   MOLECULAR CANCER THERAPEUTICS